Global Postmenopausal Vaginal Atrophy Treatment

Postmenopausal Vaginal Atrophy Treatment Comprehensive Study by Type (Prasterone (Intrarosa)), Application (Vaginal estrogen cream (Estrace, Premarin). You insert this cream directly into your vagina with an applicator, usually at bedtime. ..., Vaginal estrogen suppositories (Imvexxy)., Vaginal estrogen ring (Estring, Femring, Vaginal estrogen tablet (Vagifem).), Drug Form (Vaginal gel, Creams, Tablet, Others), Drug (Estrogen based drugs (Premarin, Vagifem, Estrace, Estring and Femring), Non-estrogen based drugs (BZA/CE, Osphena, and Vaginorm), Others), Route of Administration (Oral, Intravaginal, Others), End User (Hospitals, Specialty Clinics, Others) Players and Region - Global Market Outlook to 2029

Postmenopausal Vaginal Atrophy Treatment Market by XX Submarkets | Forecast Years 2024-2029  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Postmenopausal vaginal atrophy is the thinning of the walls of the vagina caused by decreased estrogen levels. This most commonly occurs after menopause. Women with vaginal atrophy have a greater chance of chronic vaginal infections and urinary function problems. The most common symptoms of vaginal atrophy are dryness, irritation, and pain during intercourse. The postmenopausal vaginal atrophy Treatment market is expected to grow in the future due to rising awareness about the treatment among the women and rising R& D activities for new treatments.This growth is primarily driven by Rising Prevalence of Postmenopausal Vaginal Atrophy .

AttributesDetails
Study Period2019-2029
Base Year2023
Forecast Period2023-2029
Volume UnitN
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Diseases & Therapeutic Areas sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Actavis Generics (United States), Bionovo (Saudi Arabia), Endoceutics, Inc. (Canada), Upsher-Smith Laboratories, LLC (United States), Novo Nordisk A/S (Denmark), Pfizer Inc. (United States), Teva Pharmaceutical Industries Ltd. (Isreal), Therapeutics MD, Inc. (United States), Shionogi & Company, Limited (Japan), Allergan plc (Ireland), Ligand Pharmaceuticals (United States) and Bayer HealthCare LLC (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In Mar 2020, Menlo Therapeutics Inc announced the completion of its merger with Foamix Pharmaceuticals Ltd. following the satisfaction of all closing conditions required by the merger.
In January 2022, Novo Nordisk India introduced a first-of-its-kind diabetes treatment medicine. The firm pronounced that it has launched the world's earliest and only oral semaglutide. This is the first time that the medicine has been developed in an oral form.The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations.

Influencing Trend:
High Demand for Effective Treatment for Postmenopausal Vaginal Atrophy

Market Growth Drivers:
Rising Prevalence of Postmenopausal Vaginal Atrophy and Growth in the Healthcare Infrastructure in Developing Regions

Challenges:
Stringent Government Rules and Regulations

Restraints:
Low Diagnosis Rate

Opportunities:
Rising R&D Activities in Postmenopausal Vaginal Atrophy Treatment, Growing Healthcare Industry Worldwide and Technological Advancements in the Medical Science

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Postmenopausal Vaginal Atrophy Treatment Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Postmenopausal Vaginal Atrophy Treatment Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Postmenopausal Vaginal Atrophy Treatment players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Postmenopausal Vaginal Atrophy Treatment Study Sheds Light on
— The Postmenopausal Vaginal Atrophy Treatment Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Postmenopausal Vaginal Atrophy Treatment industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Postmenopausal Vaginal Atrophy Treatment industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Prasterone (Intrarosa)
By Application
  • Vaginal estrogen cream (Estrace, Premarin). You insert this cream directly into your vagina with an applicator, usually at bedtime. ...
  • Vaginal estrogen suppositories (Imvexxy).
  • Vaginal estrogen ring (Estring, Femring
  • Vaginal estrogen tablet (Vagifem).
By Drug Form
  • Vaginal gel
  • Creams
  • Tablet
  • Others

By Drug
  • Estrogen based drugs (Premarin, Vagifem, Estrace, Estring and Femring)
  • Non-estrogen based drugs (BZA/CE, Osphena, and Vaginorm)
  • Others

By Route of Administration
  • Oral
  • Intravaginal
  • Others

By End User
  • Hospitals
  • Specialty Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Postmenopausal Vaginal Atrophy
      • 3.2.2. Growth in the Healthcare Infrastructure in Developing Regions
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. High Demand for Effective Treatment for Postmenopausal Vaginal Atrophy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Postmenopausal Vaginal Atrophy Treatment, by Type, Application, Drug Form, Drug, Route of Administration, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Postmenopausal Vaginal Atrophy Treatment (Value)
      • 5.2.1. Global Postmenopausal Vaginal Atrophy Treatment by: Type (Value)
        • 5.2.1.1. Prasterone (Intrarosa)
      • 5.2.2. Global Postmenopausal Vaginal Atrophy Treatment by: Application (Value)
        • 5.2.2.1. Vaginal estrogen cream (Estrace, Premarin). You insert this cream directly into your vagina with an applicator, usually at bedtime. ...
        • 5.2.2.2. Vaginal estrogen suppositories (Imvexxy).
        • 5.2.2.3. Vaginal estrogen ring (Estring, Femring
        • 5.2.2.4. Vaginal estrogen tablet (Vagifem).
      • 5.2.3. Global Postmenopausal Vaginal Atrophy Treatment by: Drug Form (Value)
        • 5.2.3.1. Vaginal gel
        • 5.2.3.2. Creams
        • 5.2.3.3. Tablet
        • 5.2.3.4. Others
      • 5.2.4. Global Postmenopausal Vaginal Atrophy Treatment by: Drug (Value)
        • 5.2.4.1. Estrogen based drugs (Premarin, Vagifem, Estrace, Estring and Femring)
        • 5.2.4.2. Non-estrogen based drugs (BZA/CE, Osphena, and Vaginorm)
        • 5.2.4.3. Others
      • 5.2.5. Global Postmenopausal Vaginal Atrophy Treatment by: Route of Administration (Value)
        • 5.2.5.1. Oral
        • 5.2.5.2. Intravaginal
        • 5.2.5.3. Others
      • 5.2.6. Global Postmenopausal Vaginal Atrophy Treatment by: End User (Value)
        • 5.2.6.1. Hospitals
        • 5.2.6.2. Specialty Clinics
        • 5.2.6.3. Others
      • 5.2.7. Global Postmenopausal Vaginal Atrophy Treatment Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
  • 6. Postmenopausal Vaginal Atrophy Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Actavis Generics (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bionovo (Saudi Arabia)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Endoceutics, Inc. (Canada)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Upsher-Smith Laboratories, LLC (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novo Nordisk A/S (Denmark)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Teva Pharmaceutical Industries Ltd. (Isreal)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Therapeutics MD, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Shionogi & Company, Limited (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Allergan plc (Ireland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Ligand Pharmaceuticals (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Bayer HealthCare LLC (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Postmenopausal Vaginal Atrophy Treatment Sale, by Type, Application, Drug Form, Drug, Route of Administration, End User and Region (value) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global Postmenopausal Vaginal Atrophy Treatment (Value)
      • 7.2.1. Global Postmenopausal Vaginal Atrophy Treatment by: Type (Value)
        • 7.2.1.1. Prasterone (Intrarosa)
      • 7.2.2. Global Postmenopausal Vaginal Atrophy Treatment by: Application (Value)
        • 7.2.2.1. Vaginal estrogen cream (Estrace, Premarin). You insert this cream directly into your vagina with an applicator, usually at bedtime. ...
        • 7.2.2.2. Vaginal estrogen suppositories (Imvexxy).
        • 7.2.2.3. Vaginal estrogen ring (Estring, Femring
        • 7.2.2.4. Vaginal estrogen tablet (Vagifem).
      • 7.2.3. Global Postmenopausal Vaginal Atrophy Treatment by: Drug Form (Value)
        • 7.2.3.1. Vaginal gel
        • 7.2.3.2. Creams
        • 7.2.3.3. Tablet
        • 7.2.3.4. Others
      • 7.2.4. Global Postmenopausal Vaginal Atrophy Treatment by: Drug (Value)
        • 7.2.4.1. Estrogen based drugs (Premarin, Vagifem, Estrace, Estring and Femring)
        • 7.2.4.2. Non-estrogen based drugs (BZA/CE, Osphena, and Vaginorm)
        • 7.2.4.3. Others
      • 7.2.5. Global Postmenopausal Vaginal Atrophy Treatment by: Route of Administration (Value)
        • 7.2.5.1. Oral
        • 7.2.5.2. Intravaginal
        • 7.2.5.3. Others
      • 7.2.6. Global Postmenopausal Vaginal Atrophy Treatment by: End User (Value)
        • 7.2.6.1. Hospitals
        • 7.2.6.2. Specialty Clinics
        • 7.2.6.3. Others
      • 7.2.7. Global Postmenopausal Vaginal Atrophy Treatment Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Postmenopausal Vaginal Atrophy Treatment: by Type(USD Million)
  • Table 2. Postmenopausal Vaginal Atrophy Treatment Prasterone (Intrarosa) , by Region USD Million (2018-2023)
  • Table 3. Postmenopausal Vaginal Atrophy Treatment: by Application(USD Million)
  • Table 4. Postmenopausal Vaginal Atrophy Treatment Vaginal estrogen cream (Estrace, Premarin). You insert this cream directly into your vagina with an applicator, usually at bedtime. ... , by Region USD Million (2018-2023)
  • Table 5. Postmenopausal Vaginal Atrophy Treatment Vaginal estrogen suppositories (Imvexxy). , by Region USD Million (2018-2023)
  • Table 6. Postmenopausal Vaginal Atrophy Treatment Vaginal estrogen ring (Estring, Femring , by Region USD Million (2018-2023)
  • Table 7. Postmenopausal Vaginal Atrophy Treatment Vaginal estrogen tablet (Vagifem). , by Region USD Million (2018-2023)
  • Table 8. Postmenopausal Vaginal Atrophy Treatment: by Drug Form(USD Million)
  • Table 9. Postmenopausal Vaginal Atrophy Treatment Vaginal gel , by Region USD Million (2018-2023)
  • Table 10. Postmenopausal Vaginal Atrophy Treatment Creams , by Region USD Million (2018-2023)
  • Table 11. Postmenopausal Vaginal Atrophy Treatment Tablet , by Region USD Million (2018-2023)
  • Table 12. Postmenopausal Vaginal Atrophy Treatment Others , by Region USD Million (2018-2023)
  • Table 13. Postmenopausal Vaginal Atrophy Treatment: by Drug(USD Million)
  • Table 14. Postmenopausal Vaginal Atrophy Treatment Estrogen based drugs (Premarin, Vagifem, Estrace, Estring and Femring) , by Region USD Million (2018-2023)
  • Table 15. Postmenopausal Vaginal Atrophy Treatment Non-estrogen based drugs (BZA/CE, Osphena, and Vaginorm) , by Region USD Million (2018-2023)
  • Table 16. Postmenopausal Vaginal Atrophy Treatment Others , by Region USD Million (2018-2023)
  • Table 17. Postmenopausal Vaginal Atrophy Treatment: by Route of Administration(USD Million)
  • Table 18. Postmenopausal Vaginal Atrophy Treatment Oral , by Region USD Million (2018-2023)
  • Table 19. Postmenopausal Vaginal Atrophy Treatment Intravaginal , by Region USD Million (2018-2023)
  • Table 20. Postmenopausal Vaginal Atrophy Treatment Others , by Region USD Million (2018-2023)
  • Table 21. Postmenopausal Vaginal Atrophy Treatment: by End User(USD Million)
  • Table 22. Postmenopausal Vaginal Atrophy Treatment Hospitals , by Region USD Million (2018-2023)
  • Table 23. Postmenopausal Vaginal Atrophy Treatment Specialty Clinics , by Region USD Million (2018-2023)
  • Table 24. Postmenopausal Vaginal Atrophy Treatment Others , by Region USD Million (2018-2023)
  • Table 25. South America Postmenopausal Vaginal Atrophy Treatment, by Country USD Million (2018-2023)
  • Table 26. South America Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 27. South America Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 28. South America Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 29. South America Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 30. South America Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 31. South America Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 32. Brazil Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 33. Brazil Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 34. Brazil Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 35. Brazil Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 36. Brazil Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 37. Brazil Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 38. Argentina Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 39. Argentina Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 40. Argentina Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 41. Argentina Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 42. Argentina Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 43. Argentina Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 44. Rest of South America Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 45. Rest of South America Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 46. Rest of South America Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 47. Rest of South America Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 48. Rest of South America Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 49. Rest of South America Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 50. Asia Pacific Postmenopausal Vaginal Atrophy Treatment, by Country USD Million (2018-2023)
  • Table 51. Asia Pacific Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 52. Asia Pacific Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 53. Asia Pacific Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 54. Asia Pacific Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 55. Asia Pacific Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 56. Asia Pacific Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 57. China Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 58. China Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 59. China Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 60. China Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 61. China Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 62. China Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 63. Japan Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 64. Japan Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 65. Japan Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 66. Japan Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 67. Japan Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 68. Japan Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 69. India Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 70. India Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 71. India Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 72. India Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 73. India Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 74. India Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 75. South Korea Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 76. South Korea Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 77. South Korea Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 78. South Korea Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 79. South Korea Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 80. South Korea Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 81. Taiwan Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 82. Taiwan Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 83. Taiwan Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 84. Taiwan Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 85. Taiwan Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 86. Taiwan Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 87. Australia Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 88. Australia Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 89. Australia Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 90. Australia Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 91. Australia Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 92. Australia Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 93. Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 94. Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 95. Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 96. Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 97. Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 98. Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 99. Europe Postmenopausal Vaginal Atrophy Treatment, by Country USD Million (2018-2023)
  • Table 100. Europe Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 101. Europe Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 102. Europe Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 103. Europe Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 104. Europe Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 105. Europe Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 106. Germany Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 107. Germany Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 108. Germany Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 109. Germany Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 110. Germany Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 111. Germany Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 112. France Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 113. France Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 114. France Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 115. France Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 116. France Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 117. France Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 118. Italy Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 119. Italy Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 120. Italy Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 121. Italy Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 122. Italy Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 123. Italy Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 124. United Kingdom Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 125. United Kingdom Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 126. United Kingdom Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 127. United Kingdom Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 128. United Kingdom Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 129. United Kingdom Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 130. Netherlands Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 131. Netherlands Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 132. Netherlands Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 133. Netherlands Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 134. Netherlands Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 135. Netherlands Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 136. Rest of Europe Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 137. Rest of Europe Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 138. Rest of Europe Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 139. Rest of Europe Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 140. Rest of Europe Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 141. Rest of Europe Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 142. MEA Postmenopausal Vaginal Atrophy Treatment, by Country USD Million (2018-2023)
  • Table 143. MEA Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 144. MEA Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 145. MEA Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 146. MEA Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 147. MEA Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 148. MEA Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 149. Middle East Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 150. Middle East Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 151. Middle East Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 152. Middle East Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 153. Middle East Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 154. Middle East Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 155. Africa Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 156. Africa Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 157. Africa Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 158. Africa Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 159. Africa Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 160. Africa Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 161. North America Postmenopausal Vaginal Atrophy Treatment, by Country USD Million (2018-2023)
  • Table 162. North America Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 163. North America Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 164. North America Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 165. North America Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 166. North America Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 167. North America Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 168. United States Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 169. United States Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 170. United States Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 171. United States Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 172. United States Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 173. United States Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 174. Canada Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 175. Canada Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 176. Canada Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 177. Canada Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 178. Canada Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 179. Canada Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 180. Mexico Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2018-2023)
  • Table 181. Mexico Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2018-2023)
  • Table 182. Mexico Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2018-2023)
  • Table 183. Mexico Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2018-2023)
  • Table 184. Mexico Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2018-2023)
  • Table 185. Mexico Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2018-2023)
  • Table 186. Company Basic Information, Sales Area and Its Competitors
  • Table 187. Company Basic Information, Sales Area and Its Competitors
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Postmenopausal Vaginal Atrophy Treatment: by Type(USD Million)
  • Table 199. Postmenopausal Vaginal Atrophy Treatment Prasterone (Intrarosa) , by Region USD Million (2024-2029)
  • Table 200. Postmenopausal Vaginal Atrophy Treatment: by Application(USD Million)
  • Table 201. Postmenopausal Vaginal Atrophy Treatment Vaginal estrogen cream (Estrace, Premarin). You insert this cream directly into your vagina with an applicator, usually at bedtime. ... , by Region USD Million (2024-2029)
  • Table 202. Postmenopausal Vaginal Atrophy Treatment Vaginal estrogen suppositories (Imvexxy). , by Region USD Million (2024-2029)
  • Table 203. Postmenopausal Vaginal Atrophy Treatment Vaginal estrogen ring (Estring, Femring , by Region USD Million (2024-2029)
  • Table 204. Postmenopausal Vaginal Atrophy Treatment Vaginal estrogen tablet (Vagifem). , by Region USD Million (2024-2029)
  • Table 205. Postmenopausal Vaginal Atrophy Treatment: by Drug Form(USD Million)
  • Table 206. Postmenopausal Vaginal Atrophy Treatment Vaginal gel , by Region USD Million (2024-2029)
  • Table 207. Postmenopausal Vaginal Atrophy Treatment Creams , by Region USD Million (2024-2029)
  • Table 208. Postmenopausal Vaginal Atrophy Treatment Tablet , by Region USD Million (2024-2029)
  • Table 209. Postmenopausal Vaginal Atrophy Treatment Others , by Region USD Million (2024-2029)
  • Table 210. Postmenopausal Vaginal Atrophy Treatment: by Drug(USD Million)
  • Table 211. Postmenopausal Vaginal Atrophy Treatment Estrogen based drugs (Premarin, Vagifem, Estrace, Estring and Femring) , by Region USD Million (2024-2029)
  • Table 212. Postmenopausal Vaginal Atrophy Treatment Non-estrogen based drugs (BZA/CE, Osphena, and Vaginorm) , by Region USD Million (2024-2029)
  • Table 213. Postmenopausal Vaginal Atrophy Treatment Others , by Region USD Million (2024-2029)
  • Table 214. Postmenopausal Vaginal Atrophy Treatment: by Route of Administration(USD Million)
  • Table 215. Postmenopausal Vaginal Atrophy Treatment Oral , by Region USD Million (2024-2029)
  • Table 216. Postmenopausal Vaginal Atrophy Treatment Intravaginal , by Region USD Million (2024-2029)
  • Table 217. Postmenopausal Vaginal Atrophy Treatment Others , by Region USD Million (2024-2029)
  • Table 218. Postmenopausal Vaginal Atrophy Treatment: by End User(USD Million)
  • Table 219. Postmenopausal Vaginal Atrophy Treatment Hospitals , by Region USD Million (2024-2029)
  • Table 220. Postmenopausal Vaginal Atrophy Treatment Specialty Clinics , by Region USD Million (2024-2029)
  • Table 221. Postmenopausal Vaginal Atrophy Treatment Others , by Region USD Million (2024-2029)
  • Table 222. South America Postmenopausal Vaginal Atrophy Treatment, by Country USD Million (2024-2029)
  • Table 223. South America Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 224. South America Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 225. South America Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 226. South America Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 227. South America Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 228. South America Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 229. Brazil Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 230. Brazil Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 231. Brazil Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 232. Brazil Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 233. Brazil Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 234. Brazil Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 235. Argentina Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 236. Argentina Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 237. Argentina Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 238. Argentina Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 239. Argentina Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 240. Argentina Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 241. Rest of South America Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 242. Rest of South America Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 243. Rest of South America Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 244. Rest of South America Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 245. Rest of South America Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 246. Rest of South America Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 247. Asia Pacific Postmenopausal Vaginal Atrophy Treatment, by Country USD Million (2024-2029)
  • Table 248. Asia Pacific Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 249. Asia Pacific Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 250. Asia Pacific Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 251. Asia Pacific Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 252. Asia Pacific Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 253. Asia Pacific Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 254. China Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 255. China Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 256. China Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 257. China Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 258. China Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 259. China Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 260. Japan Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 261. Japan Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 262. Japan Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 263. Japan Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 264. Japan Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 265. Japan Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 266. India Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 267. India Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 268. India Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 269. India Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 270. India Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 271. India Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 272. South Korea Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 273. South Korea Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 274. South Korea Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 275. South Korea Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 276. South Korea Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 277. South Korea Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 278. Taiwan Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 279. Taiwan Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 280. Taiwan Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 281. Taiwan Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 282. Taiwan Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 283. Taiwan Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 284. Australia Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 285. Australia Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 286. Australia Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 287. Australia Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 288. Australia Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 289. Australia Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 290. Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 291. Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 292. Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 293. Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 294. Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 295. Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 296. Europe Postmenopausal Vaginal Atrophy Treatment, by Country USD Million (2024-2029)
  • Table 297. Europe Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 298. Europe Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 299. Europe Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 300. Europe Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 301. Europe Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 302. Europe Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 303. Germany Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 304. Germany Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 305. Germany Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 306. Germany Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 307. Germany Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 308. Germany Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 309. France Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 310. France Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 311. France Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 312. France Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 313. France Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 314. France Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 315. Italy Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 316. Italy Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 317. Italy Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 318. Italy Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 319. Italy Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 320. Italy Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 321. United Kingdom Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 322. United Kingdom Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 323. United Kingdom Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 324. United Kingdom Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 325. United Kingdom Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 326. United Kingdom Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 327. Netherlands Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 328. Netherlands Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 329. Netherlands Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 330. Netherlands Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 331. Netherlands Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 332. Netherlands Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 333. Rest of Europe Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 334. Rest of Europe Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 335. Rest of Europe Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 336. Rest of Europe Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 337. Rest of Europe Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 338. Rest of Europe Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 339. MEA Postmenopausal Vaginal Atrophy Treatment, by Country USD Million (2024-2029)
  • Table 340. MEA Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 341. MEA Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 342. MEA Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 343. MEA Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 344. MEA Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 345. MEA Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 346. Middle East Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 347. Middle East Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 348. Middle East Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 349. Middle East Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 350. Middle East Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 351. Middle East Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 352. Africa Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 353. Africa Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 354. Africa Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 355. Africa Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 356. Africa Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 357. Africa Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 358. North America Postmenopausal Vaginal Atrophy Treatment, by Country USD Million (2024-2029)
  • Table 359. North America Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 360. North America Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 361. North America Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 362. North America Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 363. North America Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 364. North America Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 365. United States Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 366. United States Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 367. United States Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 368. United States Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 369. United States Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 370. United States Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 371. Canada Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 372. Canada Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 373. Canada Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 374. Canada Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 375. Canada Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 376. Canada Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 377. Mexico Postmenopausal Vaginal Atrophy Treatment, by Type USD Million (2024-2029)
  • Table 378. Mexico Postmenopausal Vaginal Atrophy Treatment, by Application USD Million (2024-2029)
  • Table 379. Mexico Postmenopausal Vaginal Atrophy Treatment, by Drug Form USD Million (2024-2029)
  • Table 380. Mexico Postmenopausal Vaginal Atrophy Treatment, by Drug USD Million (2024-2029)
  • Table 381. Mexico Postmenopausal Vaginal Atrophy Treatment, by Route of Administration USD Million (2024-2029)
  • Table 382. Mexico Postmenopausal Vaginal Atrophy Treatment, by End User USD Million (2024-2029)
  • Table 383. Research Programs/Design for This Report
  • Table 384. Key Data Information from Secondary Sources
  • Table 385. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Postmenopausal Vaginal Atrophy Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Postmenopausal Vaginal Atrophy Treatment: by Application USD Million (2018-2023)
  • Figure 6. Global Postmenopausal Vaginal Atrophy Treatment: by Drug Form USD Million (2018-2023)
  • Figure 7. Global Postmenopausal Vaginal Atrophy Treatment: by Drug USD Million (2018-2023)
  • Figure 8. Global Postmenopausal Vaginal Atrophy Treatment: by Route of Administration USD Million (2018-2023)
  • Figure 9. Global Postmenopausal Vaginal Atrophy Treatment: by End User USD Million (2018-2023)
  • Figure 10. South America Postmenopausal Vaginal Atrophy Treatment Share (%), by Country
  • Figure 11. Asia Pacific Postmenopausal Vaginal Atrophy Treatment Share (%), by Country
  • Figure 12. Europe Postmenopausal Vaginal Atrophy Treatment Share (%), by Country
  • Figure 13. MEA Postmenopausal Vaginal Atrophy Treatment Share (%), by Country
  • Figure 14. North America Postmenopausal Vaginal Atrophy Treatment Share (%), by Country
  • Figure 15. Global Postmenopausal Vaginal Atrophy Treatment share by Players 2023 (%)
  • Figure 16. Global Postmenopausal Vaginal Atrophy Treatment share by Players (Top 3) 2023(%)
  • Figure 17. Global Postmenopausal Vaginal Atrophy Treatment share by Players (Top 5) 2023(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Actavis Generics (United States) Revenue, Net Income and Gross profit
  • Figure 20. Actavis Generics (United States) Revenue: by Geography 2023
  • Figure 21. Bionovo (Saudi Arabia) Revenue, Net Income and Gross profit
  • Figure 22. Bionovo (Saudi Arabia) Revenue: by Geography 2023
  • Figure 23. Endoceutics, Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 24. Endoceutics, Inc. (Canada) Revenue: by Geography 2023
  • Figure 25. Upsher-Smith Laboratories, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 26. Upsher-Smith Laboratories, LLC (United States) Revenue: by Geography 2023
  • Figure 27. Novo Nordisk A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 28. Novo Nordisk A/S (Denmark) Revenue: by Geography 2023
  • Figure 29. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 31. Teva Pharmaceutical Industries Ltd. (Isreal) Revenue, Net Income and Gross profit
  • Figure 32. Teva Pharmaceutical Industries Ltd. (Isreal) Revenue: by Geography 2023
  • Figure 33. Therapeutics MD, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Therapeutics MD, Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Shionogi & Company, Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 36. Shionogi & Company, Limited (Japan) Revenue: by Geography 2023
  • Figure 37. Allergan plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 38. Allergan plc (Ireland) Revenue: by Geography 2023
  • Figure 39. Ligand Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 40. Ligand Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 41. Bayer HealthCare LLC (United States) Revenue, Net Income and Gross profit
  • Figure 42. Bayer HealthCare LLC (United States) Revenue: by Geography 2023
  • Figure 43. Global Postmenopausal Vaginal Atrophy Treatment: by Type USD Million (2024-2029)
  • Figure 44. Global Postmenopausal Vaginal Atrophy Treatment: by Application USD Million (2024-2029)
  • Figure 45. Global Postmenopausal Vaginal Atrophy Treatment: by Drug Form USD Million (2024-2029)
  • Figure 46. Global Postmenopausal Vaginal Atrophy Treatment: by Drug USD Million (2024-2029)
  • Figure 47. Global Postmenopausal Vaginal Atrophy Treatment: by Route of Administration USD Million (2024-2029)
  • Figure 48. Global Postmenopausal Vaginal Atrophy Treatment: by End User USD Million (2024-2029)
  • Figure 49. South America Postmenopausal Vaginal Atrophy Treatment Share (%), by Country
  • Figure 50. Asia Pacific Postmenopausal Vaginal Atrophy Treatment Share (%), by Country
  • Figure 51. Europe Postmenopausal Vaginal Atrophy Treatment Share (%), by Country
  • Figure 52. MEA Postmenopausal Vaginal Atrophy Treatment Share (%), by Country
  • Figure 53. North America Postmenopausal Vaginal Atrophy Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Actavis Generics (United States)
  • Bionovo (Saudi Arabia)
  • Endoceutics, Inc. (Canada)
  • Upsher-Smith Laboratories, LLC (United States)
  • Novo Nordisk A/S (Denmark)
  • Pfizer Inc. (United States)
  • Teva Pharmaceutical Industries Ltd. (Isreal)
  • Therapeutics MD, Inc. (United States)
  • Shionogi & Company, Limited (Japan)
  • Allergan plc (Ireland)
  • Ligand Pharmaceuticals (United States)
  • Bayer HealthCare LLC (United States)
Additional players considered in the study are as follows:
Pantarhei Bioscience (Netherland) , VYNE Therapeutics Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 232 Pages 65 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Postmenopausal Vaginal Atrophy Treatment Quantitative research analysis
Global Postmenopausal Vaginal Atrophy Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2019-2023; Base year: 2023; Forecast period: 2023 to 2029
Companies that are profiled in Global Postmenopausal Vaginal Atrophy Treatment Market are Actavis Generics (United States), Bionovo (Saudi Arabia), Endoceutics, Inc. (Canada), Upsher-Smith Laboratories, LLC (United States), Novo Nordisk A/S (Denmark), Pfizer Inc. (United States), Teva Pharmaceutical Industries Ltd. (Isreal), Therapeutics MD, Inc. (United States), Shionogi & Company, Limited (Japan), Allergan plc (Ireland), Ligand Pharmaceuticals (United States) and Bayer HealthCare LLC (United States) etc.
Vaginal estrogen cream (Estrace, Premarin). You insert this cream directly into your vagina with an applicator, usually at bedtime. ... segment in Global market to hold robust market share owing to "Rising Prevalence of Postmenopausal Vaginal Atrophy ".
AMA Research predicts that france Players will contribute to the maximum growth of Global Postmenopausal Vaginal Atrophy Treatment market throughout the forecasted period.

Know More About Global Postmenopausal Vaginal Atrophy Treatment Report?

Have a Query? Click Here

Other Related Reports

Meningitis Diagnostic Testing Comprehensive Study by Application (Viral Meningitis, Bacterial Meningitis, Fungal Meningitis, Hib Meningitis, Others), Test Type (Latex Agglutination Tests, Lateral Flo...
$ 3650
Hemostasis Diagnostics Comprehensive Study by Type (Laboratory Analyzers (Automated Systems, Semi-automated Systems, Manual Systems), Point-of-Care Testing Systems), Application (Hospital/Clinics, In...
$ 3750
Genetic Modification Therapies Comprehensive Study by Type (Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies, Gene Editing), Application (Hospitals, Diagnostics and Testing Laborato...
$ 3450
Brain Tumor Therapeutics Comprehensive Study by Type (MRI, CT Scan, Tissue Sampling, PET-CT Scan, Cerebral Arteriogram, Lumbar Puncture, Molecular Testing, EEG), Treatment Type (Surgery, Radiation Th...
$ 3650
Retinal Biologics Comprehensive Study by Application (Hospitals, Clinics, Research Organizations, Others), Diagnostic Tests (Amsler grid test, Optical coherence tomography (OCT), Fundus autofluoresce...
$ 3650
Enteric Empty Capsules Comprehensive Study by Type (Gelatin Capsules (Pig Meat Gelatin, Bovine-Derived Gelatin.Bone Meal, and Other Gelatin Sources), Non-Gelatin Capsules (Hydroxypropyl Methylcellulo...
$ 3750